Pulmonary hypertension alters soluble guanylate cyclase activity and expression in pulmonary arteries isolated from fetal lambs

2001 ◽  
Vol 31 (2) ◽  
pp. 97-105 ◽  
Author(s):  
Ching Tzao ◽  
Peter A. Nickerson ◽  
James A. Russell ◽  
Sylvia F. Gugino ◽  
Robin H. Steinhorn
Kardiologiia ◽  
2020 ◽  
Vol 60 (8) ◽  
pp. 115-123
Author(s):  
Z. S. Valieva ◽  
S. E. Gratsianskaya ◽  
T. V. Martynyuk

Chronic thromboembolic pulmonary hypertension (CTEPH) is a precapillary type of pulmonary hypertension with chronic obstruction of large and medium branches of pulmonary arteries along with secondary alterations in pulmonary microcirculation, which cause progressive increases in pulmonary vascular resistance and pulmonary arterial pressure and ensuing severe right heart dysfunction and heart failure. Pulmonary thromboendarterectomy (PTE) is the treatment of choice for CTEPH; however, this procedure is available not for all patients. Although the surgery performed in the conditions of centers with advanced experience generally shows good results, up to 40% of patients are technically inoperable or PTE is associated with a high risk of complications. At present, riociguat, the only officially approved drug from the class of soluble guanylate cyclase stimulators, is considered as a first-line treatment for inoperable and residual forms of STEPH. Introduction of riociguat to clinical practice can be called a real breakthrough in the treatment of patients with STEPH who cannot undergo PTE or those with relapse or persistent STEPH after the surgery.


1997 ◽  
Vol 273 (4) ◽  
pp. H1949-H1955 ◽  
Author(s):  
Michaela Straznicka ◽  
Gary Gong ◽  
James Tse ◽  
Peter M. Scholz ◽  
Harvey R. Weiss

We tested the hypothesis that cardiac myocytes from hypertensive (one kidney, one clip; 1K,1C) cardiac-hypertrophied rabbits require higher guanosine 3′,5′-cyclic monophosphate (cGMP) to similarly lower O2consumption than control myocytes and that this effect is caused by differences in guanylate cyclase activity. Using isolated myocytes from control and 1K,1C New Zealand White rabbits, we obtained O2 consumption (nl O2 ⋅ min−1 ⋅ 105cells) and cGMP (fmol/105 cells) levels after stimulation of guanylate cyclase with nitroprusside, CO, or guanylin (10−8–10−5M). Soluble guanylate cyclase activity was also determined. Basal cGMP was elevated in 1K,1C vs. control (176 ± 28 vs. 85 ± 13) myocytes. cGMP increased in 1K,1C and control myocytes after stimulation with nitroprusside, CO, and guanylin. Guanylate cyclase activity in 1K,1C vs. control myocytes was not statistically different. Basal O2 consumption in 1K,1C vs. control myocytes was comparable (307 ± 1 vs. 299 ± 22). O2 consumption was similarly decreased when guanylate cyclase was stimulated. Control regression equations correlating cGMP and O2consumption were O2 consumption = −1.46 ⋅ [cGMP] + 444.65 ( r = 0.96) for CO, O2 consumption = −0.58 ⋅ [cGMP] + 328.48 ( r = 0.82) for nitroprusside, and O2 consumption = −1.25 ⋅ [cGMP] + 389.15 ( r = 0.88) for guanylin. The 1K,1C regression equations were O2consumption = −1.36 ⋅ [cGMP] + 537.81 ( r = 0.97) for CO, O2 consumption = −0.23 ⋅ [cGMP] + 307.30 ( r = 0.88) for nitroprusside, and O2 consumption = −1.27 ⋅ [cGMP] + 502.91 ( r = 0.89) for guanylin. These data indicate that 1K,1C hypertrophic myocytes had higher cGMP than controls at every level of O2consumption. This effect was not caused by differences in basal or maximal guanylate cyclase activity.


1981 ◽  
Vol 240 (2) ◽  
pp. E79-E82
Author(s):  
D. L. Vesely

The objective of this investigation was to determine whether physiological levels of growth hormone have part of their mechanism of action through stimulation of guanylate cyclase (EC 4.6.1.2.). Rat and human growth hormones enhanced the activity of soluble guanylate cyclase two- to fourfold in rat gracilis anticus skeletal muscle, liver, lung, heart, pancreas, and kidney cortex at a concentration of 10 nM. Dose-response relationships revealed that more than half-maximal stimulation of guanylate cyclase activity was seen at a concentration as low as 10 nM and nonstimulation of guanylate cyclase activity was seen when the concentration was decreased to 1 nM. Maximal enhancement was seen at 100 nM of growth hormone, and there was no further enhancement when the concentration was increased to the micromolar or millimolar range. Thus, the data in this investigation indicate that at concentrations at which growth hormone is known to cause its growth-promoting effects, growth hormone does cause an enhancement of the activity of the guanylate cyclase-cyclic GMP system.


Sign in / Sign up

Export Citation Format

Share Document